REPLY: Revisiting ICD Therapy for Primary Prevention: The CONTEMP-ICD Trial.
Publication
, Journal Article
Yehya, A; Al-Khatib, SM
Published in: JACC Heart Fail
May 2025
Duke Scholars
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
May 2025
Volume
13
Issue
5
Start / End Page
881 / 882
Location
United States
Related Subject Headings
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Yehya, A., & Al-Khatib, S. M. (2025). REPLY: Revisiting ICD Therapy for Primary Prevention: The CONTEMP-ICD Trial. JACC Heart Fail, 13(5), 881–882. https://doi.org/10.1016/j.jchf.2025.02.010
Yehya, Amin, and Sana M. Al-Khatib. “REPLY: Revisiting ICD Therapy for Primary Prevention: The CONTEMP-ICD Trial.” JACC Heart Fail 13, no. 5 (May 2025): 881–82. https://doi.org/10.1016/j.jchf.2025.02.010.
Yehya A, Al-Khatib SM. REPLY: Revisiting ICD Therapy for Primary Prevention: The CONTEMP-ICD Trial. JACC Heart Fail. 2025 May;13(5):881–2.
Yehya, Amin, and Sana M. Al-Khatib. “REPLY: Revisiting ICD Therapy for Primary Prevention: The CONTEMP-ICD Trial.” JACC Heart Fail, vol. 13, no. 5, May 2025, pp. 881–82. Pubmed, doi:10.1016/j.jchf.2025.02.010.
Yehya A, Al-Khatib SM. REPLY: Revisiting ICD Therapy for Primary Prevention: The CONTEMP-ICD Trial. JACC Heart Fail. 2025 May;13(5):881–882.
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
May 2025
Volume
13
Issue
5
Start / End Page
881 / 882
Location
United States
Related Subject Headings
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology